Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun 1;185(6):669-678.
doi: 10.1001/jamainternmed.2025.0640.

Emergency Department Visits for Medication-Related Events With vs Without Pharmacist Intervention: The URGEIM Randomized Clinical Trial

Maxime Villiet  1 , Marion Laureau  1   2 , Damien Perier  2 , Véronique Pinzani  3 , Isabelle Giraud  4 , Laura Lohan  1   5 , Xavier Bobbia  2   6 , Grégoire Mercier  7   8 , Audrey Jaussent  9 , Valérie Macioce  9 , Mustapha Sebbane  2 , Marie Faucanié  9 , Cyril Breuker  1   5
Affiliations
Randomized Controlled Trial

Emergency Department Visits for Medication-Related Events With vs Without Pharmacist Intervention: The URGEIM Randomized Clinical Trial

Maxime Villiet et al. JAMA Intern Med. .

Abstract

Importance: Medication-related events (MREs) are a frequent cause of emergency department (ED) visits and patient harm.

Objective: To assess the efficacy of a pharmacist-led transition of care program in reducing ED visits related to the same MRE at 6 months compared with usual care.

Design, setting, and participants: This prospective, open-label, parallel-group randomized clinical trial was conducted from November 2018 to July 2021 at the ED of Montpellier University Hospital, Montpellier, France, with a 6-month follow-up period. Adult patients with an MRE detected at ED admission were included. MREs included adverse drug events with or without misuse and medication nonadherence with unfavorable clinical evolution. End points were assessed blindly from the randomization arm. Data were analyzed from January 2022 to March 2024.

Intervention: Participants were randomized to a pharmacist-led transition of care program or usual care. Usual care included the ED pharmacist carrying out a medication history. In the transition of care group, ED pharmacists additionally made a postdischarge telephone call to the general practitioner (GP) and community pharmacist, along with a letter, notifying them about MRE type, suspected medication, and management recommendations.

Main outcomes and measures: The primary outcome was the proportion of patients with an ED visit for the same MRE at 6 months (same symptom and medication involved). Secondary outcomes included proportions of all-cause and MRE-related ED visits, hospitalizations, deaths, and medical office visits.

Results: Among 330 patients analyzed, 187 (56.7%) were female, the median (IQR) age was 71 (50-83) years, and the median (IQR) home medications count was 6 (3-10). A total of 167 patients were randomized to the transition of care group and 163 to the control group. At 6 months, fewer participants in the transition of care group had ED visits related to the same MRE (5 [3.0%] vs 36 [22.1%]; risk difference [RD], -19.1 percentage points; 95% CI, -26.0 to -12.2; P < .001), all-cause ED visits (35 [21.0%] vs 57 [35.0%]; RD, -14.0 percentage points; 95% CI, -23.6 to -4.4), hospitalization related to the same MRE (3 [1.8%] vs 29 [17.8%]; RD, -16.0 percentage points; 95% CI, -22.2 to -9.8), and more GP office visits (88 of 158 [55.7%] vs 26 of 146 [17.8%]; RD, 37.9 percentage points; 95% CI, 28.0 to 47.8) and specialist office visits (67 of 158 [42.4%] vs 35 of 146 [24.0%]; RD, 18.4 percentage points; 95% CI, 8.1 to 28.8) related to the same MRE. All-cause hospitalization and death were similar between groups.

Conclusions and relevance: In this randomized clinical trial, a pharmacist-led transitional care intervention in the ED among patients with MRE significantly reduced ED visits and hospitalizations for the same MRE. If replicated in subsequent trials, this strategy offers a novel approach for reducing drug-related harms.

Trial registration: ClinicalTrials.gov Identifier: NCT03725046.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Bobbia reported personal fees from GE Healthcare outside the submitted work. Dr Breuker reported grants from the French Ministry of Health during the conduct of the study. No other disclosures were reported.

Comment on

References

    1. Schmitt E, Antier D, Bernheim C, Dufay E, Husson MC, Tissot E, eds. Dictionnaire Français de L’erreur Médicamenteuse. Société Française de Pharmacie Clinique; 2006.
    1. Hohl CM, Woo SA, Cragg A, et al. . Repeat adverse drug events associated with outpatient medications: a descriptive analysis of 3 observational studies in British Columbia, Canada. CMAJ Open. 2019;7(3):E446-E453. doi:10.9778/cmajo.20180190 - DOI - PMC - PubMed
    1. Gandhi TK, Weingart SN, Borus J, et al. . Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556-1564. doi:10.1056/NEJMsa020703 - DOI - PubMed
    1. Hohl CM, Zed PJ, Brubacher JR, Abu-Laban RB, Loewen PS, Purssell RA. Do emergency physicians attribute drug-related emergency department visits to medication-related problems? Ann Emerg Med. 2010;55(6):493-502.e4. doi:10.1016/j.annemergmed.2009.10.008 - DOI - PubMed
    1. Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38(6):666-671. doi:10.1067/mem.2001.119456 - DOI - PubMed

Associated data